Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 16 | 2020 | 693 | 3.370 |
Why?
|
| Blood Glucose | 17 | 2019 | 631 | 2.170 |
Why?
|
| Hypoglycemic Agents | 10 | 2019 | 361 | 1.330 |
Why?
|
| Hyperglycemia | 5 | 2020 | 158 | 1.270 |
Why?
|
| Insulin | 9 | 2019 | 617 | 1.200 |
Why?
|
| Diabetes Complications | 5 | 2020 | 249 | 1.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2020 | 1085 | 1.090 |
Why?
|
| Primary Health Care | 3 | 2016 | 702 | 0.680 |
Why?
|
| Practice Guidelines as Topic | 5 | 2016 | 772 | 0.670 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.670 |
Why?
|
| Disease Management | 2 | 2020 | 248 | 0.650 |
Why?
|
| Congresses as Topic | 2 | 2016 | 85 | 0.640 |
Why?
|
| Hypoglycemia | 5 | 2016 | 72 | 0.640 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.600 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.600 |
Why?
|
| Pandemics | 1 | 2020 | 346 | 0.570 |
Why?
|
| Certification | 1 | 2016 | 66 | 0.530 |
Why?
|
| Public Health | 2 | 2016 | 201 | 0.510 |
Why?
|
| Obesity | 5 | 2020 | 1074 | 0.510 |
Why?
|
| Thyroid Crisis | 1 | 2013 | 6 | 0.470 |
Why?
|
| Humans | 46 | 2020 | 68525 | 0.470 |
Why?
|
| Hospitals | 1 | 2016 | 265 | 0.470 |
Why?
|
| Hypercalcemia | 1 | 2013 | 34 | 0.470 |
Why?
|
| Societies, Medical | 1 | 2016 | 403 | 0.460 |
Why?
|
| Regional Health Planning | 1 | 2013 | 7 | 0.460 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 121 | 0.460 |
Why?
|
| Health Personnel | 1 | 2016 | 286 | 0.440 |
Why?
|
| Weight Reduction Programs | 3 | 2020 | 67 | 0.440 |
Why?
|
| Anti-Obesity Agents | 1 | 2013 | 42 | 0.440 |
Why?
|
| Periodontal Diseases | 1 | 2013 | 54 | 0.440 |
Why?
|
| Oral Health | 1 | 2013 | 49 | 0.440 |
Why?
|
| South Carolina | 11 | 2016 | 2750 | 0.430 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 109 | 0.430 |
Why?
|
| Automobile Driving | 1 | 2013 | 88 | 0.420 |
Why?
|
| Accidents, Traffic | 1 | 2013 | 109 | 0.420 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 170 | 0.400 |
Why?
|
| Cost of Illness | 1 | 2013 | 204 | 0.400 |
Why?
|
| Glucocorticoids | 1 | 2013 | 222 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2013 | 529 | 0.400 |
Why?
|
| Telemedicine | 3 | 2017 | 699 | 0.390 |
Why?
|
| Inpatients | 3 | 2020 | 208 | 0.380 |
Why?
|
| Biomarkers | 2 | 2016 | 1593 | 0.360 |
Why?
|
| Graft Survival | 1 | 2012 | 465 | 0.360 |
Why?
|
| Pediatrics | 1 | 2013 | 341 | 0.350 |
Why?
|
| Glycemic Index | 1 | 2009 | 28 | 0.350 |
Why?
|
| Kidney Transplantation | 2 | 2014 | 839 | 0.320 |
Why?
|
| Drug Dosage Calculations | 1 | 2007 | 9 | 0.320 |
Why?
|
| Inflammation | 1 | 2014 | 1030 | 0.320 |
Why?
|
| Coronary Care Units | 1 | 2007 | 12 | 0.320 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 281 | 0.320 |
Why?
|
| Hyperlipidemias | 2 | 2004 | 90 | 0.290 |
Why?
|
| Weight Loss | 3 | 2020 | 319 | 0.280 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 82 | 0.240 |
Why?
|
| Patient Education as Topic | 5 | 2017 | 424 | 0.240 |
Why?
|
| Middle Aged | 16 | 2020 | 21119 | 0.240 |
Why?
|
| Lipids | 1 | 2004 | 298 | 0.220 |
Why?
|
| Treatment Outcome | 8 | 2016 | 7028 | 0.210 |
Why?
|
| Aged | 11 | 2020 | 14842 | 0.210 |
Why?
|
| Hospitalization | 4 | 2016 | 977 | 0.200 |
Why?
|
| Overweight | 3 | 2020 | 186 | 0.200 |
Why?
|
| Diabetic Nephropathies | 2 | 2013 | 161 | 0.200 |
Why?
|
| Clinical Protocols | 2 | 2020 | 172 | 0.190 |
Why?
|
| Hyperaldosteronism | 1 | 2000 | 5 | 0.190 |
Why?
|
| Adrenal Glands | 1 | 2000 | 46 | 0.190 |
Why?
|
| Hunger | 1 | 2020 | 27 | 0.180 |
Why?
|
| Insulin, Long-Acting | 3 | 2014 | 5 | 0.180 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2019 | 26 | 0.180 |
Why?
|
| Female | 18 | 2020 | 38015 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2019 | 40 | 0.170 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 115 | 0.160 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 180 | 0.150 |
Why?
|
| Community Health Services | 1 | 1998 | 141 | 0.150 |
Why?
|
| Male | 15 | 2020 | 37281 | 0.150 |
Why?
|
| Psychosocial Support Systems | 1 | 2017 | 12 | 0.150 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2017 | 63 | 0.150 |
Why?
|
| Insulin Resistance | 2 | 1998 | 241 | 0.150 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2017 | 101 | 0.140 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2016 | 4 | 0.140 |
Why?
|
| Risk Factors | 5 | 2016 | 5719 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 1998 | 284 | 0.140 |
Why?
|
| Young Adult | 5 | 2017 | 5708 | 0.140 |
Why?
|
| Algorithms | 2 | 2014 | 1194 | 0.130 |
Why?
|
| Pancreatitis | 1 | 2017 | 279 | 0.130 |
Why?
|
| Hospitals, University | 2 | 2007 | 169 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2016 | 411 | 0.130 |
Why?
|
| Adult | 12 | 2020 | 21375 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2014 | 144 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 219 | 0.120 |
Why?
|
| Critical Care | 1 | 2016 | 263 | 0.120 |
Why?
|
| Fees and Charges | 1 | 2013 | 11 | 0.120 |
Why?
|
| Self Care | 1 | 2016 | 252 | 0.120 |
Why?
|
| Regional Medical Programs | 1 | 2013 | 22 | 0.110 |
Why?
|
| Nutrition Therapy | 1 | 2013 | 21 | 0.110 |
Why?
|
| Phentermine | 1 | 2013 | 17 | 0.110 |
Why?
|
| Adolescent Development | 1 | 2013 | 28 | 0.110 |
Why?
|
| Salivary Glands | 1 | 2013 | 52 | 0.110 |
Why?
|
| Fructose | 1 | 2013 | 51 | 0.110 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 25 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2014 | 330 | 0.110 |
Why?
|
| Pilot Projects | 2 | 2017 | 1341 | 0.110 |
Why?
|
| Safety | 1 | 2013 | 145 | 0.110 |
Why?
|
| Pneumonia | 1 | 2013 | 110 | 0.110 |
Why?
|
| Eye | 1 | 2013 | 89 | 0.110 |
Why?
|
| Mass Screening | 1 | 1998 | 837 | 0.110 |
Why?
|
| Benzazepines | 1 | 2013 | 104 | 0.110 |
Why?
|
| Mortality | 1 | 2013 | 162 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 124 | 0.100 |
Why?
|
| Stents | 2 | 2016 | 657 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2012 | 82 | 0.100 |
Why?
|
| Angioplasty, Balloon | 1 | 2012 | 110 | 0.100 |
Why?
|
| Quality of Life | 2 | 2017 | 1515 | 0.100 |
Why?
|
| Stroke | 2 | 2016 | 2161 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 648 | 0.100 |
Why?
|
| Exercise | 2 | 2016 | 657 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2014 | 458 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 174 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 4655 | 0.100 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2012 | 134 | 0.100 |
Why?
|
| Body Mass Index | 4 | 2017 | 866 | 0.090 |
Why?
|
| Insulin Glargine | 3 | 2014 | 6 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 447 | 0.090 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2009 | 20 | 0.090 |
Why?
|
| Hip Joint | 1 | 2009 | 64 | 0.080 |
Why?
|
| Incidence | 1 | 2013 | 1582 | 0.080 |
Why?
|
| Antioxidants | 3 | 2007 | 304 | 0.080 |
Why?
|
| Lipoproteins, LDL | 2 | 2004 | 343 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2014 | 2356 | 0.080 |
Why?
|
| Bone Density | 1 | 2009 | 159 | 0.080 |
Why?
|
| Research Design | 1 | 2012 | 729 | 0.080 |
Why?
|
| Hypertension | 2 | 2013 | 1531 | 0.080 |
Why?
|
| Adolescent | 3 | 2017 | 8903 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2020 | 3702 | 0.080 |
Why?
|
| Aldehyde Reductase | 1 | 2007 | 3 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2007 | 30 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 334 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 766 | 0.070 |
Why?
|
| Electronic Mail | 2 | 2017 | 29 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 711 | 0.070 |
Why?
|
| United States | 2 | 2017 | 7335 | 0.070 |
Why?
|
| Cholesterol | 3 | 2016 | 331 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 218 | 0.070 |
Why?
|
| Telephone | 2 | 2017 | 160 | 0.070 |
Why?
|
| Glycation End Products, Advanced | 1 | 2007 | 125 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2007 | 270 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 659 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 3256 | 0.060 |
Why?
|
| Internet | 1 | 2007 | 390 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 951 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2007 | 499 | 0.060 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2003 | 5 | 0.060 |
Why?
|
| Sepsis | 1 | 2006 | 233 | 0.060 |
Why?
|
| Testosterone | 1 | 2003 | 96 | 0.060 |
Why?
|
| Adrenalectomy | 2 | 2000 | 17 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2016 | 291 | 0.060 |
Why?
|
| Diabetic Angiopathies | 1 | 2004 | 203 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2004 | 238 | 0.060 |
Why?
|
| Diabetic Foot | 1 | 2002 | 33 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2002 | 91 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2016 | 1447 | 0.050 |
Why?
|
| Hormones | 1 | 2000 | 42 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2000 | 89 | 0.050 |
Why?
|
| Intensive Care Units | 2 | 2016 | 344 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2000 | 106 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 1999 | 22 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 2004 | 0.040 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1999 | 26 | 0.040 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1999 | 16 | 0.040 |
Why?
|
| Health Maintenance Organizations | 1 | 1998 | 22 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 696 | 0.040 |
Why?
|
| Office Visits | 1 | 1998 | 83 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 1998 | 23 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 1998 | 36 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2000 | 237 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 554 | 0.040 |
Why?
|
| Syndrome | 1 | 1998 | 255 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2017 | 87 | 0.040 |
Why?
|
| Albuminuria | 1 | 1998 | 171 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2000 | 705 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2016 | 32 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2009 | 7264 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2017 | 129 | 0.040 |
Why?
|
| Health Behavior | 1 | 2020 | 458 | 0.030 |
Why?
|
| Calibration | 1 | 2015 | 73 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 115 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 172 | 0.030 |
Why?
|
| Counseling | 1 | 2016 | 279 | 0.030 |
Why?
|
| Medical Errors | 1 | 2015 | 80 | 0.030 |
Why?
|
| Health Education | 1 | 2016 | 279 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1998 | 503 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 87 | 0.030 |
Why?
|
| Meals | 1 | 2013 | 14 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 1419 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2013 | 100 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1753 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 567 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2014 | 294 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 236 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 807 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2000 | 2222 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 83 | 0.020 |
Why?
|
| Oxidation-Reduction | 2 | 2004 | 567 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 83 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 938 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1449 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 73 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2004 | 94 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2004 | 346 | 0.010 |
Why?
|
| Private Practice | 1 | 2002 | 19 | 0.010 |
Why?
|
| Public Health Practice | 1 | 2002 | 23 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2004 | 718 | 0.010 |
Why?
|
| alpha-Methyltyrosine | 1 | 1999 | 6 | 0.010 |
Why?
|
| Adrenergic Antagonists | 1 | 1999 | 4 | 0.010 |
Why?
|
| Catecholamines | 1 | 1999 | 73 | 0.010 |
Why?
|
| Models, Educational | 1 | 1998 | 67 | 0.010 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1998 | 47 | 0.010 |
Why?
|
| Research | 1 | 1998 | 214 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 1996 | 17 | 0.010 |
Why?
|
| C-Peptide | 1 | 1996 | 23 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 1996 | 17 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1996 | 112 | 0.010 |
Why?
|
| Phospholipids | 1 | 1996 | 108 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 1139 | 0.010 |
Why?
|
| Triglycerides | 1 | 1996 | 184 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 1996 | 161 | 0.010 |
Why?
|
| Vitamins | 1 | 1996 | 134 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1996 | 222 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 579 | 0.010 |
Why?
|
| Pregnancy | 1 | 1999 | 2331 | 0.010 |
Why?
|